Binary Antisense Oligonucleotide Agent for Cancer Marker-Dependent Degradation of Targeted RNA

Area of Science:

• Gene therapy
• Oligonucleotide therapeutics
• Cancer biology

Background:

• Antisense oligonucleotide (ASO) technology is a successful gene therapy (GT) strategy.
• Limited selectivity of current ASO agents restricts their use as anticancer drugs.

Purpose of the Study:

• To develop a highly selective gene therapy agent for cancer treatment.
• To introduce the concept of binary antisense oligonucleotide (biASO) for targeted cancer therapy.

Main Methods:

• Designed biASO agents to recognize specific RNA sequences (markers) associated with cancer.
• Engineered biASO to activate RNase H-dependent cleavage of targeted messenger RNA specifically in cancer cells.
• Optimized biASO to minimize off-target RNA cleavage in the absence of a cancer-specific activator.

Main Results:

• Demonstrated selective activation of antisense agents within cancer cells.
• Achieved targeted messenger RNA cleavage dependent on the presence of a cancer marker.
• Minimized background cleavage, indicating enhanced specificity.

Conclusions:

• The proposed biASO approach provides a foundation for developing highly selective and efficient gene therapy agents for cancer.
• biASO technology has the potential to overcome the limitations of current antisense agents in cancer treatment.
• This strategy paves the way for more targeted and effective oligonucleotide-based cancer therapies.